Am­gen's Leah Christl makes the case to keep the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars

Am­gen and its port­fo­lio of 11 biosim­i­lars is stand­ing be­hind in­ter­change­abil­i­ty, say­ing the des­ig­na­tion should not be re­scind­ed and that the FDA needs to re­tain its reg­u­la­to­ry flex­i­bil­i­ties.

The po­si­tion puts Am­gen in op­po­si­tion to bi­par­ti­san leg­is­la­tion that’s push­ing to re­move the in­ter­change­abil­i­ty des­ig­na­tion for biosim­i­lars and to the in­dus­try-led Biosim­i­lars Fo­rum, whose ex­ec­u­tive di­rec­tor re­cent­ly told End­points News they were back­ing the push to re­move the des­ig­na­tion. The in­ter­change­abil­i­ty des­ig­na­tion al­lows biosim­i­lars to be swapped with their brand name ref­er­ence prod­ucts with­out the in­ter­ven­tion of a pre­scriber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA